Global CTL019

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

4 + 7 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

The purpose of this study is to evaluate the efficacy of Cart 19 cells therapy as measured by overall remission rate, which includes Complete Remission and Complete Remission with incomplete blood count recovery assessment in infants to adults. This study involves administer of the study drug, chemotherapy, and blood draws Reimbursement for travel may be provided. If you have questions or would like to learn more about the study, please contact the Principal Investigator, Dr. Grupp at (215) 590-5475.

ClinicalTrials.gov Identifier

NCT02435849

View full trial information on ClinicalTrials.gov

Eligibility & Criteria

IRB #:
14-011485
Official Title:
A Phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia
Study Phase:
Phase II
Eligible Age Range:
3 - 21 Years
Gender:
All
Study Categories:
Leader
Stephan A. Grupp

Stephan A. Grupp, MD, PhD